Research studies conducted with cancer patients are called clinical trials. As a cancer patient, you may take part in a clinical trial. Please see the links below for current open trials at UC San Francisco.
CC#22075: A Phase I Multicenter Study Evaluating the Safety and Tolerability of CGG19CART in Subjects with Relapsed or Refractory Metastatic Colorectal Cancer
NCT05319314
Contact: Harika Gopi (415)818-4579: [email protected]
CC#21708: A Phase 1/2 Study of REGN7075 (EGFR x CD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors.
NCT04626635
Contact: Sylvan Muellerleile (415)309-0245: [email protected]
Colorectal Non-Therapeutic Studies
CC#134510: GIMP: Molecular Profiling in Gastrointestinal Malignancies
Contact: Banaz Shwan (415) 205-8214: [email protected]
CC#21456: Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
NCT05056077
Contact: Miriam Oseguera (415) 215-4475: [email protected],
https://toolstobefit.eurekaplatform.org/
For information on Early Phase clinical trials not listed please contact:
[email protected]
No trials at this time.
CC#194522: Phase II Trial of Durvalumab (MEDI4736) with/without Tremelimumab for Advanced Hepatocellular Carcinoma after Palliative Hypofractionated Radiotherapy
NCT04430452
Contact: Luchia Andemicael (415) 476-8099: [email protected]
CC#204517: A Phase 1b/2, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Advanced Liver Cancers (Morpheus-Liver)
NCT04524871
Contact: Sandy He (415) 671-9917: [email protected]
CC#234510: A Multicenter, Open-label, First-in-Human Study of TYRA-200 in Advanced Intrahepatic Cholangiocarcinoma and Other Solid Tumors with Activating FGFR2 Gene Alterations (SURF-201)
NCT06160752
Contact: Sandy He (415) 671-9917: [email protected]
CC#244512: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer
NCT06467357
Contact: Corona Smith (415) 205-4812 [email protected]
CC#244519: A Multicenter, Open-label, First-in-Human Study of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors with Activating FGF/FGFR pathway aberrations (SURF-431)
Contact: Sandy He (415) 671-9917: [email protected]
Hepatocellular and Biliary Tract Non-Therapeutic Studies
CC#124512: Banking of Human Biological Specimens for Hepatobiliary Cancer Research Studies: UCSF Hepatobiliary Tissue Bank and Registry
Contact: Sandy He (415) 671-9917: [email protected]
For information on Immunotherapy trials not listed please contact:
[email protected]
CC#22457: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)
Contact: Mina Mahdi (415-205-8117): [email protected]
CC# 22958 Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors NCT05746208
Contact: Phu Lam (415) 818-7994: [email protected]
CC#23708: DAREON™-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas
NCT05882058
Contact: Kira Chan (415) 309-1810: [email protected]
CC#23702: A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and, HPN328 with Atezolizumab or Ifinatamab Deruxtecan (I-DXd) in Patients with Advanced Cancers Associated with Expression of Delta-like Canonical Notch Ligand 3 (DLL3)
NCT04471727
Contact: Stefanie Chen, [email protected]
Neuroendocrine Tumors Non-Therapeutic Studies
CC#194520: NET Voices: A Pilot Study Using a Web-Based Health Platform to Investigate Health-Related Quality of Life in Patients with Neuroendocrine Tumors
Contact: Farhana Moon: [email protected], [email protected]
https://enet.eurekaplatform.org/
CC#224514: Study of Maintenance Ivaltinostat plus Capecitabine or Capecitabine Monotherapy in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on First Line FOLFIRINOX Chemotherapy
NCT05249101
Contact: Evelyn Montenegro (415) 218-8398: [email protected]
A021806: A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
NCT04340141
Contact: Amy Zeng 415-215-6489: [email protected]
A022106: Phase II/III Second-Line Nabplagem Vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)
NCT06115499
Contact: Amy Zeng 415-215-6489: [email protected]
CC#23453: A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination with VS-6766 and Defactinib in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas
NCT05669482
Contact: Luke Getchell (415)218-7472: [email protected]
CC#23456: A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX Alone in Patients with Resected Pancreatic Ductal Adenocarcinoma
NCT05968326
Contact: Luke Getchell (415)218-7472: [email protected]
CC#244515: A Phase 3 Multicenter, Open-label, Randomized Study of RMC-6236 versus Investigator’s Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06625320
Contact: Insiyah Merchant (415)215-4632: [email protected]
CC#21951: LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participants with an Advanced Solid Tumor NCT04939610
Contact: Brad Kline (415)353-9448: [email protected]
CC#249513: PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours That are MTAP Deficient
NCT06130553
Contacts: Cindy Zhang (415)987-4261: [email protected]; Zach Schoenherr (415)987-5675: [email protected]
CC#24709: Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects with Advanced or Metastatic Solid Tumors NCT06105021
Contact: Gyula Kangiszer (415)539-6946: [email protected]
CC#244516: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma Not Previously Treated in the Metastatic Setting
NCT06608927
Contact: Amy Zeng 415-215-6489: [email protected]
Pancreatic Non-Therapeutic Studies
CC#224524: Pancreatic Cancer Early Detection (PRECEDE) Consortium
NCT04970056
Contact: Rachael Leigh Delacruz (415) 476-2874: [email protected]
CC25703: A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients with Solid Tumors that Harbor the p53 R175H Mutation NCT06778863 Contact: Marissa Gin (415)307-5697: [email protected]
CC25703: A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients with Solid Tumors that Harbor the p53 R175H Mutation
NCT06778863
Contact: Marissa Gin (415)307-5697: [email protected]
CC#25454: A Phase 1/2, Open-Label, Dose Escalation and Expansion Study with PT886 followed by a Multi-cohorT Study in Patients With Advanced GastrIc, Gastroesophageal JuNction (GEJ), or Pancreatic Ductal AdEnocarcinomas of PT886, in Combination with either ChemotherApy, and/or the ChecKpoint Inhibitor Pembrolizumab.
NCT05482893
Contact: Kevin Lopez (415) 502-3110: [email protected]
For information on Early Phase clinical trials not listed please contact:
[email protected]
For information on Immunotherapy trials not listed please contact:
[email protected]